The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
MS Treatments
Jahr
Publikationsjahr
2017
Autoren
Autorenliste der Publikation
Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.
Verlag
Publisher-Information
J Neuroinflammation. 2017 Aug 31;14(1):172.
Link
Zur Publikation (externer Server)
https://doi.org/10.1186/s12974-017-0945-z
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
2017
COVID-19 and multiple sclerosis: challenges and lessons for patient care
Multiple Sclerosis
Jahr
2024
A future of AI-driven personalized care for people with multiple sclerosis
MASC
Jahr
2024
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons
MS Treatments
Jahr
2024
Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER
MS Treatments
Jahr
2024
Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA
MS Treatments
Jahr
2024
